100000 - Document - Document and Entity Information
link:presentationLink
link:calculationLink
link:definitionLink
100010 - Statement - Condensed Consolidated Balance Sheets
link:presentationLink
link:calculationLink
link:definitionLink
100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)
link:presentationLink
link:calculationLink
link:definitionLink
100030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)
link:presentationLink
link:calculationLink
link:definitionLink
100040 - Statement - Condensed Consolidated Statements of Changes in Stockholder's Equity (Unaudited)
link:presentationLink
link:calculationLink
link:definitionLink
100050 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)
link:presentationLink
link:calculationLink
link:definitionLink
995455 - Disclosure - Nature of Organization and Operations
link:presentationLink
link:calculationLink
link:definitionLink
995465 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies
link:presentationLink
link:calculationLink
link:definitionLink
995475 - Disclosure - Product Revenues, Accounts Receivable, and Reserves for Product Sales
link:presentationLink
link:calculationLink
link:definitionLink
995485 - Disclosure - Inventory
link:presentationLink
link:calculationLink
link:definitionLink
995495 - Disclosure - Prepaid and Other Current Assets
link:presentationLink
link:calculationLink
link:definitionLink
995505 - Disclosure - Development Liability
link:presentationLink
link:calculationLink
link:definitionLink
995515 - Disclosure - Accrued Expenses
link:presentationLink
link:calculationLink
link:definitionLink
995525 - Disclosure - Long-term Debt
link:presentationLink
link:calculationLink
link:definitionLink
995535 - Disclosure - Leases
link:presentationLink
link:calculationLink
link:definitionLink
995545 - Disclosure - Fair Value Measurements
link:presentationLink
link:calculationLink
link:definitionLink
995555 - Disclosure - Income Taxes
link:presentationLink
link:calculationLink
link:definitionLink
995565 - Disclosure - License and Collaboration Agreements
link:presentationLink
link:calculationLink
link:definitionLink
995575 - Disclosure - Commitments and Contingencies
link:presentationLink
link:calculationLink
link:definitionLink
995585 - Disclosure - Net Loss per Share
link:presentationLink
link:calculationLink
link:definitionLink
995595 - Disclosure - Subsequent Events
link:presentationLink
link:calculationLink
link:definitionLink
995605 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)
link:presentationLink
link:calculationLink
link:definitionLink
995615 - Disclosure - Product Revenues, Accounts Receivable, and Reserves for Product Sales (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995625 - Disclosure - Inventory (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995635 - Disclosure - Prepaid and Other Current Assets (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995645 - Disclosure - Development Liability (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995655 - Disclosure - Accrued Expenses (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995665 - Disclosure - Long-term Debt (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995675 - Disclosure - Leases (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995685 - Disclosure - Fair Value Measurements (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995695 - Disclosure - Net Loss per Share (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995705 - Disclosure - Nature of Organization and Operations - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995715 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995725 - Disclosure - Product Revenues, Accounts Receivable, and Reserves for Product Sales - Schedule of Disaggregation of Product Revenue by Major Source (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995735 - Disclosure - Product Revenues, Accounts Receivable, and Reserves for Product Sales - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995745 - Disclosure - Product Revenues, Accounts Receivable, and Reserves for Product Sales - Summary of Product Revenue Allowance and Reserve Categories (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995755 - Disclosure - Product Revenues, Accounts Receivable, and Reserves for Product Sales - Schedule of Customer Accounted for 10% of More of Gross Product Revenues and Accounts Receivable (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995765 - Disclosure - Inventory - Schedule of Inventory Current (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995775 - Disclosure - Inventory - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995785 - Disclosure - Prepaid and Other Current Assets - Summary of Prepaid and Other Current Assets (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995795 - Disclosure - Prepaid and Other Current Assets - Summary of Prepaid and Other Current Assets (Parenthetical) (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995805 - Disclosure - Prepaid and Other Current Assets - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995815 - Disclosure - Development Liability - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995825 - Disclosure - Leases - Maturities of Operating Lease Liabilities (Detail) 2
link:presentationLink
link:calculationLink
link:definitionLink
995835 - Disclosure - Development Liability - Summary of Development Liability (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995845 - Disclosure - Development Liability - Schedule of Future Minimum SFJ Payments (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995855 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995865 - Disclosure - Long-term Debt - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995875 - Disclosure - Long-term Debt - Schedule of Outstanding Balance of Convertible Notes (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995885 - Disclosure - Long-term Debt - Schedule of Interest Expense Recognized Related to Convertible Notes (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995895 - Disclosure - Long-term Debt - Schedule of Future Minimum Payments on Convertible Notes Payable (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995905 - Disclosure - Leases - Schedule of Additional Information Related to Operating Lease Assets and Liabilities (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995915 - Disclosure - Leases - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995925 - Disclosure - Leases - Supplemental Cash Flow Information Related to Operating Leases (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995935 - Disclosure - Leases - Maturities of Operating Lease Liabilities (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995945 - Disclosure - Fair Value Measurements - Schedule of Financial Instruments and the Related Fair Value Hierarchy of the Valuation Techniques Utilized (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995955 - Disclosure - Fair Value Measurements - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995965 - Disclosure - Income Taxes - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995975 - Disclosure - License and Collaboration Agreements - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995985 - Disclosure - Commitments and Contingencies - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995995 - Disclosure - Net Loss per Share - Summary of Shares Outstanding that were Excluded from Calculation of Diluted Net Loss Per Share (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
Product sales reserves.
Product Sales Reserves
Product sales reserves
Convertible Debt
Convertible notes
Convertible Debt, Total
2025
Lessee, Operating Lease, Liability, to be Paid, Year One
Collaborative Arrangement and Arrangement Other than Collaborative [Domain]
Collaborative Arrangement and Arrangement Other than Collaborative
Document Transition Report
Document Transition Report
Interest Expense, Debt [Abstract]
Money Market Funds [Member]
Money Market Funds [Member]
Convertible senior notes due two thousand twenty six.
Convertible Senior Notes Due Two Thousand Twenty Six [Member]
Convertible Senior Notes Due 2026 [Member]
Development milestone achievement.
Development Milestone Achievement
Development milestone achievement
Debt Instruments [Abstract]
Other Liabilities, Noncurrent, Total
Other Liabilities, Noncurrent
Other liabilities
Contract research and development other current assets.
Contract Research and Development Other Current Assets
Contract research and development receivable other current assets
Restricted Stock Units (RSUs) [Member]
Restricted Stock Units [Member]
Fair Value, Inputs, Level 1 [Member]
Level 1 [Member]
Accrued research and development
Accrued Research And Development Current
Accrued research and development current.
Fair Value Disclosures [Text Block]
Fair Value Measurements
Development liability current.
Development Liability Current
Current portion of development liability
Total revenue
Revenue
Revenue from Contract with Customer, Excluding Assessed Tax
Total Product revenue, net
Remaining reimbursement payment
Remaining Reimbursement Payment
Remaining reimbursement payment.
Prepaid Expense and Other Assets, Current [Abstract]
Empaveli And Aspaveli [Member]
EMPAVELI and Aspaveli [Member]
EMPAVELI and Aspaveli member
Disaggregation of Revenue [Table Text Block]
Schedule of Disaggregation of Product Revenue by Major Source
Concentration Risk Type [Axis]
Customer D.
Customer D [Member]
Customer D [Member]
non-refundable upfront payment.
Non Refundable Upfront Payment
Non-refundable Upfront Payment
Aggregate milestone payments upon achievement of specified one time regulatory development and commercial milestone events
Aggregate Milestone Payments Upon Achievement of Specified One Time Regulatory Development and Commercial Milestone Events
Aggregate milestone payments upon achievement of specified one time regulatory development and commercial milestone events.
Long-Term Debt, Percentage Bearing Fixed Interest, Amount
Less: interest
Subsequent Events
Subsequent Events [Text Block]
Research and Development [Abstract]
Convertible senior notes.
Convertible Senior Notes Noncurrent
Convertible notes
Lease liabilities
Operating Lease, Liability, Noncurrent
Debt Instrument, Unamortized Discount
Debt discount
Debt Instrument, Unamortized Discount, Total
Product revenues, accounts receivable, and reserves for product sales.
Product Revenues Accounts Receivable And Reserves For Product Sales [Line Items]
Product Revenues Accounts Receivable And Reserves For Product Sales [Line Items]
Balance Sheet Location [Axis]
Balance Sheet Location
Assets, Current
Total current assets
Liabilities and Equity
Total liabilities and stockholders' equity
Entity Address, State or Province
Entity Address, State or Province
Annual license maintenance fees.
Annual License Maintenance Fees
Annual maintenance fees
Stock Issued During Period, Value, New Issues
Common Stock -follow-on-offering
Collaborative arrangement, number of research programs.
Collaborative Arrangement Number Of Research Programs
Number of research programs
Sales milestone payments based on achievement of annual sales milestones.
Sales Milestone Payments Based On Achievement Of Annual Sales Milestones
Milestone payments based on annual sales milestones
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Comprehensive loss, net of tax
Product revenue allowances and reserves, credit and payments made.
Product Revenue Allowances And Reserves, Credit And Payments Made
Credits and payments made
Inventory Disclosure [Text Block]
Inventory
Trading Symbol
Trading Symbol
Common Stock, Shares, Issued
Common stock, issued
Common Stock, Shares, Issued, Total
Refund filed under CARES Act relating to employee retention credit.
Refund Filed under CARES Act Relating to Employee Retention Credit
Refund filed under CARES Act relating to employee retention credit
2026
Long-Term Debt, Maturity, Year Two
David Watson [Member]
David Watson.
Schedule of Long-Term Debt Instruments [Table]
Debt Instrument [Table]
Maximum credit per employee for each calendar quarter.
Maximum Credit per Employee for Each Calendar Quarter
Maximum credit per employee for each calendar quarter
Shares, Outstanding
Ending balance, Shares
Beginning balance, Shares
Litigation Settlement, Amount Awarded to Other Party
Incurred any cost to defend lawsuits or settle claims
2027
Lessee, Operating Lease, Liability, to be Paid, Year Three
AOCI Attributable to Parent [Member]
Total Accumulated Other Comprehensive Income (Loss) [Member]
Accumulated Other Comprehensive Income/(Loss) [Member]
Second annual payment under agreement
Second Annual Payment Under Agreement
Second annual payment under agreement.
Amortization of discounts for convertible notes
Amortization Of Discounts For Convertible Notes
Amortization of discounts for convertible notes.
Entity Address, City or Town
Entity Address, City or Town
2024
Long-Term Debt, Maturity, Remainder of Fiscal Year
Operating Lease, Weighted Average Discount Rate, Percent
Weighted Average discount rate used to measure outstanding lease liabilities
Development derivative liabilities current.
Development Derivative Liabilities Current
Current portion of development liability, net of discount
Less: Current portion of development liability, net of discount
Debt Disclosure [Text Block]
Long-term Debt
Subsequent Event [Member]
Subsequent Event [Member]
Subsequent Event Type [Axis]
2020 Convertible notes.
Two Thousand Twenty Convertible Notes [Member]
2020 Convertible Notes [Member]
Royalties entitled to receive after first commercial sale of applicable licensed product period
Royalties Entitled To Receive After First Commercial Sale Of Applicable Licensed Product Period
Royalties entitled to receive after first commercial sale of applicable licensed product period.
Additional Paid-in Capital [Member]
Additional Paid-In Capital [Member]
Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale
Proceeds from maturity of available-for-sale securities
Inventory, Raw Materials, Gross, Total
Inventory, Raw Materials, Gross
Raw materials
Collaboration and license agreement.
Collaboration And License Agreement [Member]
Collaboration and License Agreement [Member]
Liabilities, Current [Abstract]
Current liabilities:
Assets, Current [Abstract]
Current assets:
Accounts Receivable, Allowance for Credit Loss, Current
Accounts receivable, net of discount and allowance
Counterparty Name [Axis]
Counterparty Name
Stock Issued During Period, Shares, Period Increase (Decrease)
Increase in shares outstanding
Stock Issued During Period, Shares, Period Increase (Decrease), Total
SFJ agreement [member].
S F J Agreement [Member]
SFJ Agreement [Member]
Preferred Stock, Par or Stated Value Per Share
Preferred stock, par value
Premium paid for capped call transaction.
Premium Paid For Capped Call Transaction
Premium paid for capped call transactions
Statement of Stockholders' Equity [Abstract]
Change in accounting principle, accounting standards update, immaterial effect [true false]
Collaborative arrangement, maximum extendable term of agreement.
Collaborative Arrangement Maximum Extendable Term Of Agreement
Collaboration agreement maximum extendable term
Current portion of lease liabilities
Operating Lease, Liability, Current
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]
Schedule of Financial Instruments and the Related Fair Value Hierarchy of the Valuation Techniques Utilized
Debt Instrument, Maturity Date
Maturity date
Regulatory milestone payments based on achievement.
Regulatory Milestone Payments Based On Achievement
Regulatory milestone payments
Long-Term Debt
Long-term debt
Net carrying amount
Property, Plant and Equipment, Net
Property and equipment, net
Property, Plant and Equipment, Net, Total
Property, Plant and Equipment, Net, Beginning Balance
Property, Plant and Equipment, Net, Ending Balance
Proceeds from contract research and development
Proceeds From Contract Research And Development
Proceeds from contract research and development .
U.S. federal statutory rate
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent
Scenario [Domain]
Scenario
2019 Convertible notes.
Two Thousand Nineteen Convertible Notes [Member]
2019 Convertible Notes [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Collaborative Arrangement and Arrangement Other than Collaborative
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]
Entity Central Index Key
Entity Central Index Key
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]
Change in accounting principle accounting standards update adopted
Increase (Decrease) in Other Current Assets
Other current assets
Assets, Noncurrent [Abstract]
Non-current assets:
Assets, Fair Value Disclosure, Total
Assets, Fair Value Disclosure
Total Financial Assets
Preferred Stock, Shares Outstanding
Preferred stock, outstanding
Preferred Stock, Shares Outstanding, Beginning Balance
Preferred Stock, Shares Outstanding, Ending Balance
Liabilities, Current
Total current liabilities
Entity Tax Identification Number
Entity Tax Identification Number
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest
Net loss before taxes
Net loss before taxes
Interest expense nonoperating.
Interest Expense Nonoperating
Interest expense
Interest Expense
Interest expense
Stockholders' Equity, Period Increase (Decrease)
Decrease in net equity
Decrease in net equity
Stockholders' Equity, Period Increase (Decrease), Total
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]
Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]
Increase (Decrease) in Operating Capital [Abstract]
Changes in operating assets and liabilities:
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
European medicines agency.
European Medicines Agency [Member]
Regulatory Approval Granted by EMA [Member]
Payments of Debt Issuance Costs
Payments of transactions cost
Financial Instruments [Domain]
Financial Instruments
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Lessee, Operating Leases [Text Block]
Leases
Lessee Operating Lease Liability Payments Due Year Four And Thereafter
Lessee operating lease liability payments due year four and thereafter.
2027 and thereafter
Implied cost of borrowing discount rates.
Implied Cost Of Borrowing Discount Rates
Implied cost of borrowing discount rates
Percentage of cost of borrowing
Product revenue allowances and reserves.
Product Revenue Allowances and Reserves
Beginning Balance
Ending balance
Lessee, Operating Lease, Term of Contract
Operating lease, term of contract
Assets
Total assets
Karen L Lewis [Member]
Karen L Lewis.
Right-of-use assets
Operating Lease, Right-of-Use Asset
Right-of-use assets
Development derivative liabilities.
Development Derivative Liabilities
Development liability
Development liability
Entity Registrant Name
Entity Registrant Name
Debt Issuance Costs, Net
Debt issuance costs
Debt Issuance Costs, Net, Total
Lessee, Lease, Description [Line Items]
Lessee Lease Description [Line Items]
Related Party, Type [Domain]
Retained Earnings (Accumulated Deficit)
Accumulated deficit
Retained Earnings (Accumulated Deficit), Total
Retained Earnings (Accumulated Deficit), Beginning Balance
Retained Earnings (Accumulated Deficit), Ending Balance
Nur Nicholson [Member]
Nur Nicholson.
Additional funding amount upon achievement of development milestones.
Additional Funding Amount Upon Achievement Of Development Milestones
Additional funding amount upon achievement of development milestones
Payment of convertible debt discounts and commissions.
Payment Of Convertible Debt Discounts And Commissions
Payment of convertible debt discounts and commissions
Retained Earnings [Member]
Accumulated Deficit [Member]
Retained Earnings [Member]
Gain (Loss) on Disposition of Assets, Total
Gain (Loss) on Disposition of Assets
Loss on disposal of fixed assets
Minimum [Member]
Minimum [Member]
Proceeds from Stock Options Exercised
Proceeds from exercise of stock options
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]
Summary of Prepaid and Other Current Assets
Revenue, Major Customer [Line Items]
Revenue, Major Customer [Line Items]
Operating Lease, Liability
Operating Lease Liabilities
Operating Lease, Liability, Total
Total operating lease liabilities
Forecast [Member]
Number of milestone payments.
Number Of Milestone Payments
Number of milestone payments
Call transactions remaining is a notional amount
Derivative Liability, Notional Amount
US Government Agencies Debt Securities [Member]
U.S. Government-Related Obligations [Member]
US Government Obligations [Member]
Equity Component [Domain]
Equity Component
Common Stock Options [Member]
Exchange agreements.
Exchange Agreements [Member]
Exchange Agreements [Member]
Change in Accounting Principle, Accounting Standards Update, Adoption Date
Change in accounting principle accounting standards update adoption date
Liability component.
Liability Component [Member]
Liability Component [Member]
Debt instrument convertible threshold trading price per principal amount.
Debt Instrument Convertible Threshold Trading Price Per Principal Amount
Trading price per principal amount
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]
Adjustments to reconcile net loss to net cash used in operating activities:
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net
Less: debit discount and issuance costs, net
Measurement Frequency [Axis]
Measurement Frequency
Debt Disclosure [Abstract]
Entity Current Reporting Status
Entity Current Reporting Status
Common Stock, Shares Authorized
Common stock, shares authorized
Research and Development Expense
Research and development
Research and Development Expense, Total
Fair Value, by Balance Sheet Grouping [Table]
Fair Value By Balance Sheet Grouping [Table]
Product revenue allowance and reserves.
Product Revenue Allowance and Reserves [Member]
Product Revenue Allowance and Reserves [Member]
Debt Instrument, convertible, initial conversion price.
Debt Instrument Convertible Initial Conversion Price
Initial conversion price
Debt Conversion, Converted Instrument, Amount
Convertible Notes exchanged for common stock
Aggregate principal amount converted
Assets [Abstract]
Assets
Number of additional annual payments.
Number Of Additional Annual Payments
Number of additional annual payments
Proceeds from issuance of common stock
Proceeds from Issuance of Common Stock
Proceeds from issuance of common stock, net of issuance costs
Common stock, $0.0001 par value; 200,000 shares authorized at March 31, 2024 and December 31, 2023; 121,267 shares issued and outstanding at March 31, 2024, and 119,556 shares issued and outstanding at December 31, 2023
Common Stock, Value, Issued
Common Stock, Value, Issued, Total
Common Stock, Value, Issued, Beginning Balance
Common Stock, Value, Issued, Ending Balance
Debt Instrument, Convertible, Conversion Price
Conversion price
Two thousand ten license agreement.
Two Thousand Ten License Agreement [Member]
2010 License Agreement [Member]
Accrued Liabilities, Current
Accrued expenses
Total accrued expenses
Current Fiscal Year End Date
Current Fiscal Year End Date
Share-Based Payment Arrangement, Noncash Expense
Share-based compensation expense
Share-based Payment Arrangement, Noncash Expense, Total
Operating Income (Loss)
Net operating loss
Convertible notes held in treasury.
Convertible Notes Held in Treasury
Convertible notes held in treasury
SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]
Income Tax Expense (Benefit), Total
Income Tax Expense (Benefit)
Income tax expense
Debt Issuance Costs, Gross
Debt issuance costs gross
Revenue, Product and Service Benchmark [Member]
Gross Product Revenues [Member]
Contractual Obligation, Fiscal Year Maturity [Table Text Block]
Schedule of Future Minimum SFJ Payments
Nature of Operations [Text Block]
Nature of Organization and Operations
Accounts Payable and Accrued Liabilities Disclosure [Text Block]
Accrued Expenses
Concentration Risk, Percentage
Concentration risk
Payment, Tax Withholding, Share-Based Payment Arrangement
Payments of employee tax withholding related to equity-based compensation
Two thousand nineteen convertible notes and two thousand twenty convertible notes member.
Two Thousand Nineteen Convertible Notes And Two Thousand Twenty Convertible Notes [Member]
2019 Convertible Notes And 2020 Convertible Notes [Member]
Product revenue reserves
Product revenue reserves current
Product revenue reserves current.
Forfeiture of accrued interest in exchange of convertible notes.
Forfeiture Of Accrued Interest In Exchange Of Convertible Notes
Forfeiture of accrued interest in exchange of convertible notes
Deferred Revenue
Deferred Revenue
Deferred Revenue, Total
Other Comprehensive Income (Loss), Net of Tax [Abstract]
Other comprehensive gain/(loss):
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations
Effect of exchange rate changes on cash, cash equivalents and restricted cash
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]
Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets:
License [Member]
License [Member]
Debt Instrument, Face Amount
Principal amount
Product revenue allowances and reserves, provision related to sales in the current year.
Product Revenue Allowances And Reserves, Provision Related To Sales In The Current Year
Provision related to sales in the current year
Other (expense)/ income, net
Other Nonoperating Income (Expense)
Other Nonoperating Income (Expense), Total
Regulatory Agency [Axis]
Regulatory Agency
Operating Expenses [Abstract]
Operating expenses:
Commitments and contingencies.
Commitments And Contingencies [Line Items]
Commitments And Contingencies [Line Items]
Maximum number of employees with employers eligible for refundable tax credit.
Maximum Number of Employees with Employers Eligible for Refundable Tax Credit
Maximum number of employees with employers eligible for refundable tax credit
Long-Term Debt, Type [Domain]
Long-term Debt, Type
2028
Contractual Obligation, to be Paid, Year Four
Subsequent Events [Abstract]
Payments for development liability
Payments for development liability
Payments For Development Liability
Payments for development liability.
Commitments and Contingencies Disclosure [Abstract]
Other Assets, Noncurrent
Other assets
Other Assets, Noncurrent, Total
Other Accrued Liabilities, Current
Other
Aggregate amount of additional annual payments.
Aggregate Amount Of Additional Annual Payments
Aggregate amount of additional annual payments
Depreciation
Depreciation expense
Depreciation, Total
Interest Paid, Excluding Capitalized Interest, Operating Activities
Cash paid for interest
Regulatory milestone incurred
Regulatory Milestone Incurred Based On Achievement
Regulatory milestone incurred based on achievement.
Additional Paid in Capital
Additional paid-in capital
Additional Paid in Capital, Total
Additional Paid in Capital, Beginning Balance
Additional Paid in Capital, Ending Balance
Licensing and other revenue.
Licensing And Other Revenue [Member]
Licensing and other revenue [Member]
Contract research and development other assets.
Contract Research and Development Other Assets
Contract research and development receivable other assets
Equity, Attributable to Parent [Abstract]
Stockholders' equity:
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Lease, Cost [Table Text Block]
Schedule of Additional Information Related to Operating Lease Assets and Liabilities
Food and drug administration.
Food And Drug Administration [Member]
Regulatory Approval Granted US Food and Drug Administration [Member]
Earnings Per Share [Abstract]
Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]
Maturities of Operating Lease Liabilities
Syfovre.
SYFOVRE [Member]
SYFOVRE [Member]
Accounting Policies [Abstract]
Lessee, Lease, Description [Table]
Lessee Lease Description [Table]
Loss on conversion of debt related to additional shares issued.
Loss On Conversion Of Debt Related To Additional Shares Issued
Loss on conversion of debt related to additional shares issued
Sales Returns and Allowances [Member]
Returns [Member]
Liability Class [Axis]
Liability Class
Scenario [Axis]
Scenario
Debt Instrument, Interest Rate, Effective Percentage
Debt instrument effective interest rate
Deposits and other current assets.
Deposits and Other Current Assets
Deposits and other current assets
Net loss per common share, basic
Net loss per common share, basic
Earnings Per Share, Basic
Customer Concentration Risk [Member]
Customer Concentration Risk [Member]
Development cost reimbursement received
Development Cost Reimbursement Received
Development cost reimbursement received.
Reserve for excess and obsolete inventory
Inventory write-downs
Inventory Write-down
Commitments and Contingencies
Commitments and contingencies (Note 14)
Prepaid and other current assets.
Prepaid and Other Current Assets [Text Block]
Prepaid and Other Current Assets
Income Statement [Abstract]
Related Party, Type [Axis]
Operating Lease, Cost
Operating lease expense
Increase (Decrease) in Prepaid Expense
Prepaid assets
Statistical Measurement [Domain]
Statistical Measurement
Net Cash Provided by (Used in) Operating Activities
Net cash used in operating activities
Development Derivative Liabilities Interest Rate Effective Percentage
Effective Interest Rate
Development derivative liabilities, interest rate, effective percentage.
Document Period End Date
Document Period End Date
Statistical Measurement [Axis]
Statistical Measurement
Commitments and Contingencies Disclosure [Text Block]
Commitments and Contingencies
Operating Lease, Payments
Operating cash flows from operating leases
Net loss per common share, diluted
Net loss per common share, diluted
Earnings Per Share, Diluted
Product and Service [Domain]
Product and Service
Empaveli (Pegcetacoplan).
EMPAVELI (Pegcetacoplan) [Member]
EMPAVELI [Member]
Unrecognized tax benefits
Unrecognized Tax Benefits
Unrecognized Tax Benefits, Ending Balance
Unrecognized Tax Benefits, Beginning Balance
SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]
Concentration Risk Benchmark [Domain]
2027
Contractual Obligation, to be Paid, Year Three
Debt Instrument, Name [Domain]
Debt Instrument, Name
Fair Value Hierarchy and NAV [Domain]
Fair Value Hierarchy and NAV
Increase (Decrease) in Other Noncurrent Liabilities
Other liabilities
Annual payment
Annual Payment Of Subsequent.
Annual payment of subsequent.
Debt Instrument, Increase (Decrease), Net
Increase (decrease) in net debt
Debt Instrument, Increase (Decrease), Net, Total
Fair Value, Recurring [Member]
Fair Value, Recurring [Member]
Schedule of Maturities of Long-Term Debt [Table Text Block]
Schedule of Future Minimum Payments on Convertible Notes Payable
Upfront payment.
Upfront Payment
Upfront payment
Debt Instrument, convertible, initial conversion cap price.
Debt Instrument Convertible Initial Conversion Cap Price
Initial cap price
2024
Contractual Obligation, to be Paid, Remainder of Fiscal Year
Conversion price per principal amount
Debt Instrument Convertible Threshold Conversion Price Per Principal Amount
Debt instrument convertible threshold conversion price per principal amount.
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period
Issuance of common stock upon exercise of stock options, shares
A Sinclair Dunlop [Member]
A Sinclair Dunlop.
Liabilities and Equity [Abstract]
Liabilities and Stockholders' Equity
Accrued goods received not invoiced
Accrued Goods Received Not Invoiced Current
Accrued goods received not invoiced current.
Development funding for minimum period of operating expense
Development Funding For Minimum Period Of Operating Expense
Development funding for minimum period of operating expense
Entity Address, Postal Zip Code
Entity Address, Postal Zip Code
Debt Instrument, Convertible, Conversion Ratio
Conversion ratio
Entity Interactive Data Current
Entity Interactive Data Current
Private Placement [Member]
Private Offering [Member]
Debt Instrument, Convertible, Threshold Consecutive Trading Days
Threshold consecutive trading days
Increase (Decrease) in Accounts Payable
Accounts payable
Increase (Decrease) in Accounts Payable, Total
Proceeds from income tax refunds net of income taxes paid
Proceeds from Income Tax Refunds
Receivable from collaboration agreement current.
Receivable from Collaboration Agreement Current
Receivable from collaboration agreement
Lessee, Operating Lease, Liability, Undiscounted Excess Amount
Less Imputed interest
Debt instrument number of counterparties.
Debt Instrument Number Of Counterparties
Number of counterparties
Schedule of interest expense related to debt instruments.
Schedule Of Interest Expense Related To Debt Instruments [Table Text Block]
Schedule of Interest Expense Recognized Related to Convertible Notes
Contra research and development reimbursement current.
Contra Research And Development Reimbursement Current
Contra research and development reimbursement current
Debt Instrument, Payment Terms
Debt instrument, due and payment description
Entity Incorporation, State or Country Code
Entity Incorporation, State or Country Code
Debt conversion converted instrument additional shares issued for settlement of debt issuance cost.
Debt Conversion Converted Instrument Additional Shares Issued For Settlement Of Debt Issuance Cost
Additional shares issued for settlement of debt issuance cost paid
Equity Components [Axis]
Equity Components
Increase (Decrease) in Accounts Receivable
Accounts receivable
Contra research and development reimbursement remaining.
Contra Research And Development Reimbursement Remaining
Contra research and development reimbursement remaining
Inventory Disclosure [Abstract]
Fair value
Financial Liabilities Fair Value Disclosure
Financial Liabilities Fair Value Disclosure, Total
Local Phone Number
Local Phone Number
Sale of Stock [Axis]
Sale of Stock
Debt Conversion, Converted Instrument, Shares Issued
Aggregate principal amount converted into shares
Deferred revenue
Increase (Decrease) in Deferred Revenue
Restricted Cash, Current
Restricted cash
Statement of Cash Flows [Abstract]
Payment made under agreement.
Payment Made Under Agreement
Payment made under agreement
Debt Instrument, Redemption Period, Start Date
Redemption period, start date
Percentage of qualified wages paid to employees under employee retention credit.
Percentage of Qualified Wages Paid to Employees under Employee Retention Credit
Percentage of qualified wages paid to employees under employee retention credit
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated Other Comprehensive Income (Loss), Net of Tax
Accumulated other comprehensive loss
Accumulated Other Comprehensive Income (Loss), Net of Tax, Total
University of pennsylvania.
University Of Pennsylvania [Member]
University of Pennsylvania [Member]
Concentration Risk Benchmark [Axis]
Development Liability [Member]
Development Liability [Member]
Development liability.
Proceeds from Collaborators
Proceeds from SFJ agreement
Common Stock, Par or Stated Value Per Share
Common stock, par value
Customer A.
Customer A [Member]
Customer A [Member]
Development derivative liabilities noncurrent.
Development Derivative Liabilities Noncurrent
Total long term development liability
Total long term development liability
Debt Instrument, Interest Rate, Stated Percentage
Debt instrument, stated percentage
Convertible notes, interest rate
Long-Lived Tangible Asset [Axis]
Long-Lived Tangible Asset
Collaborative Arrangement Disclosure [Text Block]
License and Collaboration Agreements
Maximum [Member]
Maximum [Member]
Convertible Debt, Noncurrent
Convertible senior notes
2025
Contractual Obligation, to be Paid, Year One
Debt Instrument, Convertible, Threshold Trading Days
Threshold trading days
Customer C.
Customer C [Member]
Customer C [Member]
Fair Value, Inputs, Level 3 [Member]
Level 3 [Member]
APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
Share-based compensation expense
APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total
Fair Value, Recurring and Nonrecurring [Table]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]
Net (decrease) increase in cash, cash equivalents and restricted cash
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect
Contra research and development reimbursement.
Contra Research and Development Reimbursement
Contra research and development reimbursement
Bachem member.
Bachem Member
Bachem [Member]
Payables and Accruals [Abstract]
Capped call transaction.
Capped Call Transaction [Member]
Capped Call Transactions [Member]
Development liability disclosure.
Development Liability Disclosure [Text Block]
Development Liability
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
Summary of Shares Outstanding that were Excluded from Calculation of Diluted Net Loss Per Share
Debt instrument convertible carrying amount of liability component.
Debt Instrument Convertible Carrying Amount Of Liability Component
Debt instrument convertible carrying amount of liability component
James Chopas [Member]
James Chopas.
Schedule of Inventory, Current [Table Text Block]
Schedule of Inventory Current
City Area Code
City Area Code
Total Inventory
Inventory, Net
Total Inventories
Inventory
Net Cash Provided by (Used in) Operating Activities [Abstract]
Operating Activities
Customer [Domain]
Weighted-average number of common shares used in net loss per common share, basic
Weighted-average number of common shares used in net loss per common share, basic
Weighted Average Number of Shares Outstanding, Basic
Proceeds from settlement of capped call
Proceeds From Settlement Of Capped Call
Proceeds from settlement of capped call.
Inventory, Work in Process, Gross
Semi-finished goods
Net Cash Provided by (Used in) Financing Activities [Abstract]
Financing Activities
Royalties receivable current.
Royalties Receivable Current
Royalties receivable
Statement [Table]
Statement [Table]
Accounts Receivable [Member]
Product Sales Receivable [Member]
Document Fiscal Period Focus
Document Fiscal Period Focus
Lessee, Operating Lease, Liability, to be Paid
Total future minimum lease payments
2026
Lessee, Operating Lease, Liability, to be Paid, Year Two
Statement [Line Items]
Statement [Line Items]
Volume-weighted average price per share
Volume Weighted Average Price Per Share
Volume Weighted Average Price Per Share
Collaborative arrangement, up-front payment in next twelve months.
Collaborative Arrangement Up Front Payment In Next Twelve Months
Up-front payment on first anniversary of agreement on June 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Antidilutive securities excluded from computation of earnings per share, amount
Alec Machiels [Member]
Alec Machiels.
Royalty revenue
Royalty Expense
Asset Class [Domain]
Asset Class
Accounts receivable, net
Accounts Receivable, after Allowance for Credit Loss, Current
Accounts Receivable, after Allowance for Credit Loss, Current, Total
Supplemental cash flow information related to operating leases.
Supplemental Cash Flow Information Related To Operating Leases Table [Text Block]
Supplemental Cash Flow Information Related to Operating Leases
Customer [Axis]
Common Stock [Member]
Common Stock [Member]
Debt Instrument [Line Items]
Debt Instrument [Line Items]
Proceeds from issuance of common stock and pre-funded warrant offering, net of issuance costs.
Proceeds From Issuance Of Common Stock And Pre-funded Warrant Offering, Net Of Issuance Costs
Proceeds from issuance of common stock and pre-funded warrant offering, net of issuance costs
Issuance of common stock and pre-funded warrants in common stock offering.
Issuance Of Common Stock And Pre-funded Warrants In Common Stock Offering
Issuance of common stock and pre-funded warrants in common stock offering
Cash and Cash Equivalents, at Carrying Value
Cash and cash equivalents
Cash and Cash Equivalents, at Carrying Value, Total
Cash and Cash Equivalents, at Carrying Value, Beginning Balance
Cash and Cash Equivalents, at Carrying Value, Ending Balance
Other Assets, Current
Other current assets
Total other current assets
Prepaid Expense, Current
Prepaid assets
Total prepaid expenses
Entity Common Stock, Shares Outstanding
Entity Common Stock, Shares Outstanding
Inventory, Finished Goods, Gross, Total
Inventory, Finished Goods, Gross
Finished goods
Antidilutive Securities, Name [Domain]
Antidilutive Securities, Name
Accounting Standards Update 2016-13 [Member]
ASU 2016-13 [Member]
Contract research and development long term assets.
Contract Research And Development Long Term Assets
Contract research and development long-term assets
Schedule of Debt [Table Text Block]
Schedule of Outstanding Balance of Convertible Notes
Cover [Abstract]
Selling, general and administrative
Selling, General and Administrative Expense
Selling, General and Administrative Expense, Total
Document Fiscal Year Focus
Document Fiscal Year Focus
Product revenues, accounts receivable, and reserves for product sales.
Product Revenues Accounts Receivable And Reserves For Product Sales [Abstract]
Accretion of discount to development liability.
Accretion Of Discount To Development Liability
Accretion of discount to development liability
Down payments for inventory current.
Down Payments for Inventory Current
Down payments for inventory
Cash paid for income taxes
Income Taxes Paid, Net
Income Taxes Paid, Net, Total
Regulatory Agency [Domain]
Regulatory Agency
Sale of Stock [Domain]
Sale of Stock
Mark DeLong [Member]
Mark DeLong.
Number of licensed products.
Number Of Licensed Products
Number of licensed products
Operating lease right of use asset and right of use liability amortization expense reversal.
Operating Lease Right Of Use Asset And Right Of Use Liability Amortization Expense Reversal
Amortization of right-of-use assets
Contra research and development expense.
Contra Research And Development Expense
Contract research and development expense
Security Exchange Name
Security Exchange Name
Accounting Standards Update and Change in Accounting Principle [Table]
Total other comprehensive income
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
Call transactions remaining is a notional amount
call transactions remaining notional amount
call transactions remaining notional amount.
New Accounting Pronouncements, Policy [Policy Text Block]
Recently Issued Accounting Standards
Preferred Stock, Shares Issued
Preferred stock, issued
Preferred Stock, Shares Issued, Total
Preferred Stock, Shares Authorized
Preferred stock, shares authorized
Sobi agreement and another licensing transaction.
Sobi Agreement And Another Licensing Transaction [Member]
Sobi Agreement and Another Licensing Transaction [Member]
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Operating lease assets obtained in exchange for lease obligations
Milestone payment received for achievement of regulatory development milestone
Milestone Payment Received for Achievement of Regulatory Development Milestone
Milestone payment received for achievement of regulatory development milestone.
Financial Instrument [Axis]
Financial Instrument
Collaborative arrangement upfront non-refundable amount payable.
Collaborative Arrangement Upfront Non Refundable Amount Payable
Up-front non-refundable payment
Stock Issued During Period, Value, Stock Options Exercised
Issuance of common stock upon exercise of stock options
Entity Emerging Growth Company
Entity Emerging Growth Company
Proceeds from Convertible Debt
Net proceeds from the sale of the notes
Amendment Flag
Amendment Flag
Debt Instrument, Convertible, Terms of Conversion Feature
Terms of conversion
Schedule of Accrued Liabilities [Table Text Block]
Schedule of Accrued Expenses
Marketable Securities, Current
Marketable securities
Marketable Securities, Current, Total
Contract research and development current.
Contract Research And Development Current
Contract research and development current
Accounting Standards Update [Domain]
Accounting Standards Update
Basis of Accounting, Policy [Policy Text Block]
Basis of Presentation
Long term development noncurrent.
Development Liability Noncurrent
Long-term development liability
Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Abstract]
Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Abstract]
Allowance for government and other rebates.
Allowance for Government and Other Rebates [Member]
Government and Other Rebates [Member]
Payments to Acquire Debt Securities, Available-for-Sale
Purchase of available-for-sale securities
Leases [Abstract]
Loss from remeasurement of development derivative liability
Derivative, Gain (Loss) on Derivative, Net
Gain (loss) from remeasurement of development derivative liability
Loss from remeasurement of development derivative liability
Derivative, Gain (Loss) on Derivative, Net, Total
Loss from remeasurement of development derivative liability
Entity File Number
Entity File Number
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
2026
Contractual Obligation, to be Paid, Year Two
Product revenue allowances and reserves, adjustments related to prior period sales.
Product Revenue Allowances And Reserves, Adjustments Related To Prior Period Sales
Adjustments related to prior period sales
Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]
Schedule of Customer Accounted for 10% of More of Gross Product Revenues and Accounts Receivable
2024
Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year
Additional amount issued in payment of issuance costs.
Additional Amount Issued In Payment Of Issuance Costs
Additional amount issued in payment of issuance costs
OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax
Unrealized gain/(loss) on marketable securities
Unrealized gain on available-for-sale investments
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents
Cash, cash equivalents and restricted cash at end of period
Cash, cash equivalents and restricted cash at beginning of period
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Total
Total cash, cash equivalents, and restricted cash
Contractual interest expense.
Contractual Interest Expense
Contractual interest expense
Prior to March Fifteen Two Thousand and Twenty Six Convertible.
Prior To March Fifteen Two Thousand And Twenty Six Convertible [Member]
Prior to March 15, 2026 Convertible [Member]
Accounts Payable, Current
Accounts payable
Accounts Payable, Current, Total
Debt Instrument [Axis]
Debt Instrument
Collaborative arrangement, term of agreement.
Collaborative Arrangement Term Of Agreement
Collaboration agreement term
Total operating expenses:
Operating Expenses
2025
Long-Term Debt, Maturity, Year One
Loss on conversion of debt.
Loss On Conversion Of Debt
Loss on conversion of debt
Total loss on conversion of debt
Loss on conversion of debt
Preferred stock, $0.0001 par value; 10,000 shares authorized, and zero shares issued and outstanding at March 31, 2024 and December 31, 2023
Preferred Stock, Value, Issued
Preferred Stock, Value, Issued, Total
Preferred Stock, Value, Issued, Beginning Balance
Preferred Stock, Value, Issued, Ending Balance
Entity Small Business
Entity Small Business
Entity Shell Company
Entity Shell Company
Bachem and NOF Corporation [Member]
Bachem and NOF Corporation [Member]
Bachem and NOF
Contract research and development receivable.
Contract Research And Development Receivable
Contract research and development receivable
Royalty expense incurred
Royalty Expense Incurred
Royalty expense incurred.
Liabilities, Noncurrent [Abstract]
Long-term liabilities:
Restricted Stock, Shares Issued Net of Shares for Tax Withholdings
Vesting of restricted stock units, net of shares withheld for taxes. shares
Earnings Per Share [Text Block]
Net Loss per Share
Revenues [Abstract]
Revenue:
Entity Address, Address Line One
Entity Address, Address Line One
Development cost reimbursement.
Development Cost Reimbursement
Development cost reimbursement
Contractual Obligation
Obligated to pay initial payment
Aggregate milestones payments
Total future minimum payments
Contract research and development reimbursement commitment.
Contract Research And Development Reimbursement Commitment
Contract research and development reimbursement commitment
Antidilutive Securities [Axis]
Antidilutive Securities
Two thousand nineteen and two thousand twenty convertible notes.
Two Thousand Nineteen And Two Thousand Twenty Convertible Notes [Member]
2019 and 2020 Convertible Notes [Member]
Restricted Cash
Restricted cash
Restricted Cash, Total
Contra research and development reimbursement long term assets.
Contra Research and Development Reimbursement Long Term Assets
Contra research and development reimbursement long-term assets
Product revenue reserves and allowances.
Product Revenue Reserves And Allowances [Table Text Block]
Summary of Product Revenue Allowance and Reserve Categories
Subsequent Event Type [Domain]
Jeffrey R Eisele [Member]
Jeffrey R Eisele [Member]
Long-Term Debt, Maturity, Year Three
2026
Restricted Stock, Value, Shares Issued Net of Tax Withholdings
Vesting of restricted stock units, net of shares withheld for taxes
Amortization of Debt Discount (Premium)
Amortization of debt discounts
Aggregate milestone payments upon achievement of specified one-time regulatory and commercial milestone events.
Aggregate Milestone Payments Upon Achievement Of Specified One Time Regulatory And Commercial Milestone Events
Aggregate milestone payments upon achievement of specified one-time regulatory and commercial milestone events
Long-Term Debt, Type [Axis]
Long-term Debt, Type
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
Net loss
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total
Fair Value, Nonrecurring [Member]
Fair Value, Nonrecurring [Member]
Long-Term Purchase Commitment, Amount
Non-cancellable purchase commitments
Debt Instrument, Frequency of Periodic Payment
Debt instrument, frequency of periodic payment
Fair Value, Inputs, Level 2 [Member]
Level 2 [Member]
Product [Member]
Product Revenue, Net [Member]
Product revenue, net [Member]
Share Price
Sale price
Collaborative Arrangement and Arrangement Other than Collaborative [Table]
Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]
Long-Term Debt, Gross
Principal
Total future minimum payments
Product and Service [Axis]
Product and Service
Accrued payroll liabilities
Accrued Payroll Liabilities Current
Accrued payroll liabilities.
Title of 12(b) Security
Security 12b Title
Convertible senior notes.
Convertible Senior Notes [Member]
Convertible Senior Notes [Member]
Accounting Standards Update [Axis]
Accounting Standards Update
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger
Threshold percentage of stock price trigger
Net Cash Provided by (Used in) Investing Activities [Abstract]
Investing Activities
Amortization of Debt Issuance Costs
Amortization of debt issuance costs
Minimum percentage of tax position likelihood of being realized upon examination by taxing authorities.
Minimum Percentage Of Tax Position Likelihood Of Being Realized Upon Examination By Taxing Authorities
Minimum percentage of tax position likelihood of being realized upon examination by taxing authorities
Beam Therapeutics, Incorporation.
Beam Therapeutics Incorporation [Member]
Beam [Member]
Long-Lived Tangible Asset [Domain]
Long-Lived Tangible Asset
Payment of convertible debt offering expenses.
Payment Of Convertible Debt Offering Expenses
Payment of convertible debt offering expenses
Increase (Decrease) in Inventories
Inventory
Increase (Decrease) in Inventories, Total
Vehicles [Member]
Vehicles [Member]
Interest Expense, Debt
Debt interest expense
Total interest expense
Common Stock, Shares, Outstanding
Common stock, outstanding
Common Stock, Shares, Outstanding, Beginning Balance
Common Stock, Shares, Outstanding, Ending Balance
Bachem Americas Inc.
Bachem Americas Inc [Member]
Bachem Americas, Inc [Member]
Accrued Royalties, Current
Accrued royalties
Other non-cancellable purchase commitments
Other Commitment, Total
Other Commitment
Other Commitment
Concentration Risk Type [Domain]
Document Type
Document Type
Stock Issued During Period, Shares, Conversion of Convertible Securities
Shares issued
Issuance of shares in exchange of Convertible Notes, including issuance costs, shares
Accounting Standards Update 2020-06 [Member]
ASU 2020-06 [Member]
Other Prepaid Expense, Current
Other prepaid expenses
Fair Value by Liability Class [Domain]
Fair Value by Liability Class
Net cash used in investing activities
Net Cash Provided by (Used in) Investing Activities
License fees
License Fees
License fees.
Document Quarterly Report
Document Quarterly Report
Equity component.
Equity Component [Member]
Equity Component [Member]
Counterparty Name [Domain]
Counterparty Name
Caroline Baumal [Member]
Caroline Baumal [Member]
Product revenues, accounts receivable, and reserves for product sales.
Product Revenues Accounts Receivable And Reserves For Product Sales [Text Block]
Product Revenues, Accounts Receivable, and Reserves for Product Sales
Waived Payment
Waived Payment
Waived payment.
Net Cash Provided by (Used in) Financing Activities
Net cash provided by financing activities
Entity Filer Category
Entity Filer Category
Cedric Francois [Member]
Cedric Francois.
Product revenues, accounts receivable, and reserves for product sales.
Product Revenues Accounts Receivable And Reserves For Product Sales [Table]
Product Revenues Accounts Receivable And Reserves For Product Sales [Table]
Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]
Supplemental Disclosure of Financing Activities
Balance Sheet Location [Domain]
Balance Sheet Location
Increase (Decrease) in Other Noncurrent Assets
Other assets
Increase (Decrease) in Accrued Liabilities
Accrued expenses
Increase (Decrease) in Accrued Liabilities, Total
Accounting Standards Update 2018-18 [Member]
ASC Topic 808
Foreign currency translation
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax
Foreign currency gain (loss)
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total
Issuance of common stock and pre-funded warrants in common stock offering, shares
Issuance Of Common Stock And Pre-funded Warrants In Common Stock Offering, Shares
Issuance of common stock and pre-funded warrants in common stock offering, shares
Asset Class [Axis]
Asset Class
Summary Of Development Derivative Liability [Table Text Block]
Summary of Development Liability
Summary of development derivative liability.
Accrued liabilities, current.
Accrued Liabilities Current [Member]
Accrued Expenses [Member]
Liabilities
Total liabilities
Equity, Attributable to Parent
Ending balance
Beginning balance
Total stockholders' equity
Impact of adoption of ASU 2020-06
Debt conversion converted instrument additional shares issued.
Debt Conversion Converted Instrument Additional Shares Issued
Additional shares issued
Net loss
Interest Expense
Non-cash interest expense
Interest Expense, Total
Sublicense fee owed.
Sublicense Fee Owed
Sublicense fee owed
Statement of Financial Position [Abstract]
Convertible notes.
Convertible Notes [Member]
Convertible Notes [Member]
Basis of Presentation and Significant Accounting Policies [Text Block]
Basis of Presentation and Summary of Significant Accounting Policies
Royalty revenue
Royalty Revenue
Royalty revenue.
Weighted-average number of common shares used in net loss per common share, diluted
Weighted-average number of common shares used in net loss per common share, diluted
Weighted Average Number of Shares Outstanding, Diluted
Operating cost of sales.
Operating Cost Of Sales
Cost of sales
Development Derivative Liabilities Unamortized Discount
Less: Unamortized discount to development liability
Development derivative liabilities, unamortized discount.
Operating Lease, Weighted Average Remaining Lease Term
Weighted Average Remaining Term in years
Debt Instrument, Redemption Price, Percentage
Redemption price, percentage
Use of Estimates, Policy [Policy Text Block]
Use of Estimates
Income Taxes
Income Tax Disclosure [Text Block]
Investment Income, Nonoperating
Interest income
Investment Income, Nonoperating, Total
Swedish Orphan Biovitrum AB (Publ).
Swedish Orphan Biovitrum A B Publ [Member]
Swedish Orphan Biovitrum AB (Publ) [Member]
Increase in additional funding for development costs.
Increase In Additional Funding For Development Costs
Increase in additional funding for development costs
Research collaboration agreement.
Research Collaboration Agreement [Member]
Research Collaboration Agreement [Member]
Commitments And Contingencies [Table]
Commitments And Contingencies [Table]
Commitments And Contingencies [Table]
Interest Expense, Debt, Excluding Amortization
Accrued semi annual coupon payable
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Fair Value Disclosures [Abstract]
Allowance for chargebacks discounts and fees.
Allowance for Chargebacks Discounts and Fees [Member]
Chargebacks, Discounts, and Fees [Member]
Fair Value Hierarchy and NAV [Axis]
Fair Value Hierarchy and NAV
Measurement Frequency [Domain]
Measurement Frequency
Payments to Acquire Property, Plant, and Equipment
Purchase of property and equipment
Payments to Acquire Property, Plant, and Equipment, Total
Stock Issued During Period, Shares, New Issues
Common Stock -follow-on-offering, shares
Income Tax Disclosure [Abstract]
First annual payment under agreement
First Annual Payment Under Agreement
First annual payment under agreement.
Prepaid research and development current.
Prepaid Research and Development Current
Prepaid research and development